Recurrent Squamous Cell Lung Carcinoma Active Not Recruiting Phase 2 Trials for Talazoparib (DB11760)

IndicationStatusPhase
DBCOND0044226 (Recurrent Squamous Cell Lung Carcinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03377556Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerTreatment